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1159MP-167 Sustained Elevation of B-Type Natriuretic Peptide 
Concentrations in Patients With Left Ventricular 
Remodeling After Myocardial Infarction 
1159MP-169 Right Ventricular Systolic Dysfunction Correlates With 
Adverse Left Ventricular Remodeling in Patients With 
Advanced Heart Failure 
Atsushi Hiravama, Yasunori &da, Masahiko Shimizu, lsamu Mizote, Masaya Usami, 
Kazuhisa Kodama. Osaka Police Hospital, Osaka, Japan 
Theodore J. Kolias William F. Armstrong, Keith D. Aaronson, University of Michigan, 
Ann Arbor, Ml 
Objectives: The aim of this study is to clarify the serial change in plasma brain natriuretic 
peptide (BNP) concentration along with left ventricular (LV) remodeling. Methods: 
Plasma BNP concentrations were measured by the radioimmunoassay in 92 patients 
with first anterior myocardial infarction at 1 (IM), 6 (6M) and 16 months (16M) after the 
onset. LV volumes were calculated by LV grams at 1M and 16M. Significant dilatation of 
end-diastolic volume, defined as increment more than 10 ml/m’ from 1M to lEM, was 
observed in 32 patients (group D) and not in 60 patients(group N). Results: There were 
no significant differences in patients’ characteristics and LV functions at tM. Plasma 
BNP concentration at 1M of group D was significantly higher than that of group N 
(268*70 vs. 120+21 pg./ml; pcO.01). Plasma BNP concentrations in both groups 
decreased significantly from 1 M to 6M (p<O.Ol), and plasma BNP concentration of group 
D was Still significantly hlgher than that of group N (123*34 vs. 49*9 pg./ml; p.zO.01). 
Plasma BNP concentrations did not change significantly after 6M in both groups, but 
plasma BNP concentration was still significantly higher m group D than group N (74+30 
vs. 33*10 pg./ml; ~~0.01). Conclusion: Plasma BNP concentration decreased indepen- 
dent of LV dilatation within 6M after the onset, however its sustamed elevation of plasma 
BNP level was o 
bserved in patients with LV remodeling. 
Background: Right ventricular dysfunction occurs to a variable degree in left heart fail- 
ure, with a number of factors potentially influencing its development. Newer echocardio- 
graphic techniques of Doppler-derived dP/dt and -dP/dt allow the quantification of RV 
and LV svstolic and diastolic function. In this studv we investiaated multiole oarameters 
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of LV size and function as possible associates of RV systolic dysfunction (assessed by 
Dopoler-derived RV dP/dt). Methods: We studied 40 oatients with advanced chronic 
heeh failure (age 61 f 15 iears; EF 23 * 10%: ischemic etiology 55%; NYHA Class 2,3. 
or 4 symptoms in 1, 25, and 14 patients, respectively). Doppler-derived RV dP/dt was 
determined in each patient from the contmuous-wave Doppler spectrum of the tricuspid 
regurgitation jet (RV dP/dt = 12ltime between 1 and 2 m/s). Doppler-derived LV dP/dt 
and -dP/dt were determined from the continuous-wave Doppler spectrum of the mitral 
regurgitation jet (LV dP/dt = 32/time between 1 and 3 m/s; LV -dP/dt = 32Itime between 3 
and 1 m/s). Other echocardiographic variables included LV end-systolic and end-dias- 
tolic diameters, LVEF, EIA ratio, severity of MA and TR. and peak TR pressure gradient. 
Results: RV dP/dt was significantly associated with LV end-systolic diameter (r = -0.43, 
p = 0.006), LV end-diastolic diameter (I = -0.42, p = 0.007), LV -dP/dt (r = 0.37, p = 
0.020), and LV dP/dt (r = 0.32, p = 0.042). In contrast, RV dP/dt was not significantly 
associated with LVEF, MR or TR severity, peak TR pressure gradient, or a “restrictive” E/ 
A. With multivariable linear regression modeling, if either LV end-systolic or LV end-dias- 
tolic diameter was included, neither LV dP/dt nor LV -dP/dt remained significant indepen- 
dent predictors of RV dP/dt. When all univanable predictors were evaluated, the only 
Independent predictor of RV dP/dt was LV end-systolic diameter. Conclusion: Adverse 
LV remodeling, marked by increased LV end-systolic and end-diastolic diameters, is an 
important marker of RV systolic dysfunction in patients with advanced heart failure. 
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1159MP-170 Carvedilol Increases Ejection Fraction and Decreases 
Left Ventricular Diameters in Patients With Severe Heart 
Failure of lschemic and Nonischemic Etiology: Results 
From the EFICAT Multicenter Trial 
Chnstiane E. Anqermann, A. Costard-Jaeckle, M. C. Deng, for the EFICAT Multicenter 
Trial Group, Medizinische Poliklinik, University of Wuerzburg, Wuerzburg, Germany 
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Serum Aldosterone Is Associated With Left Ventricular 
Remodeling in Women but Not Men: Framingham Heart 
Study 
Ramachandran S. Vasan, Jane C. Evans, Emelia J. Benjamin, Daniel Levy, Martin G. 
Larson, Johan Sundstrom. Flora Sam, Wilson S. Colucci, Peter W. Wilson, Framingham 
Heart Study, Framingham, MA, Boston University School of MedIcme, Boston. MA 
Background: Aldosterone IS associated with myocardial fibrosis in experimental studies, 
and with LV remodelmg in CHF patients. We hypothesized that aldosterone influences 
LV remodeling in people without CHF in the community. 
Methods: We studied 1027 subjects (mean age 56years, 59% women) without CHF or MI 
who had sewn aldosterone measured and underwent routine echocardiography. 
Results: Aldosterone levels were similar in men and women. In sex-specific regression- 
adjusting for age, systolic BP, weight, height, diabetes, heart rate and hypertenswn treat- 
ment- aldosterone was positively associated with LV mass (LVM), wall thickness (LVWT) 
and relative wall thickness (RWT) in women but not in men (Table). Aldosterone was not 
related to LV dimensions 01 systolic function in either sex. 
COnChiOnS: In our community-based sample, serum aldosterone was associated with 
increased LVM and LVWT, and altered LV geometry in women but not men. Additional 
investigations are warranted to elucidate the mechanism of these gender-related differ- 
ences in aldosterone effect. 
Serum Aldosteronc and LV Measures* 
Aldosterone Quartiles 
LVM. gm 
LVWT, cm 
RWT 
LVM. gm 
LVWT. cm 
RWT 
Ql Q2 
WOMEN 
137 140 
1.77 1.60 
0 40 0.40 
MEN 
197 195 
2.05 2.03 
0.41 0.41 
Q3 04 P (Trend) 
143 143 0.04 
1.65 1.85 <O.OOl 
0.41 0.42 <O.OOl 
192 199 0.93 
2.03 2.06 0.61 
0.41 041 0.78 
‘LV meaSureS adjusted for age. SBP. weight, height, dtabetes, heart rate and HTN Rx. 
Background: In severe heart failure(CHF) or transplant candidates(HTC) improved SUP 
viva1 & cardiac function were shown on carvedilol(C), but the impact of CHF etiology on 
the effect of C on ejection fraction(EF) and capacity to influence LV remodeling in HTC 
are unclear. 
Method: A double blind, placebo(P) controlled 12 months trial was conducted in 3 Ger- 
man transplant centers. HTC with cardiomegaly and CHF were eligible. Endpoints were 
changes from baseline to latest available value of LVEF(RNV) and LV enddiastolic and 
endsystolic dimenslons(EDD, ESD, echo)in C- and P-treated HTC. 
Results: The trial prospectively randomized 118 HTC (53.k9.6 years) with end stage 
CHF of ischemic (I. n=44) or non-ischemic (NI, n=74) etiology and a mean LVEF at base- 
line of 19.!&6.6 (20.1)% with a change of +6.0+9.3 (+3.9)% in the C-treated and 
+0.7+7.1 (O.O)% in the P-treated group (pcO.008, Wilcoxon two-sided test). In the sub- 
groups, the change in LVEF was in HTC-I +5.2+7.0 (+4.0)% in the C-treated vs. -5.3_+ 
6.8 (-5.5)% in the P-treated group (p.zO.03); in HTC-NI the change in LVEF was 
+9&l 1.6 (+8.0) % in the C-treated vs. +2.7+7.6 (O.O)% in the P-treated group (p<O.O4). 
The mean EDD and ESD at baseline were 73.@.2 (74.0)mm and 64.7i9.0 (64.0) mm 
in the C-treated and 75.6+9.1 (74.0) and 66.3210.0 (66.5)mm in the P-treated group (all 
NS). These values decreased significantly in the C-, but not the P-treated group (~~0.03 
and p=O.O5, resp.). In the subgroups, the changes in EDD were in HTC-I +2.3$6 
(+l.O)mm in the C- and +4.3+.3 (+4.0)mm in the P-treated group, in HTC-NI -3.026.2 (- 
3.0)mm in the C- and +1 .k_7.1 (+l .O)mm in the P-treated group. The changes in ESD 
were !n HTC-I +0.4&7 (O.O)mm in the C- and +2.7+8.6 (+2.0)mm in the P-treated group, 
in HTC-NI -6.k7.5 (-5.0)mm in the C-and -1.2i7.3 (-2.0)mm in the P-treated group. 
Conclwon: Even in HTC with end stage CHF C-therapy improves significantly LVEF 
over a prolonged period of time irrespective of CHF etiology. While the significant 
decrease m mean ESD mainly corresponds to improved pumping performance, the con- 
comitant significant decrease in mean EDD observed particularly in HTC with NI-CHF 
suggests reverse remodelling induced by C-treatment even m these Individuals. 
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1159MP-171 Heart Failure Following ST Elevation Myocardial 
Infarction: Are We Aggressive Enough? 
Amir Kashani Sabina A. Murphy, Elliott M. Amman, Robelt P. Giugliano, TIMI Study -I 
Group, Rochester General Hospital, Rochester, NY, Brigham 8 Women’s Hospital, 
Boston, MA 
Background: Prior studies suggest heart failure (HF) complicating myocardial infarction 
(MI) is associated with poor prognosis, thus current guidelines emphawe early catheter- 
ization. Data are sparse regarding differences in treatment across the spectrum of HF fol- 
lowing fibrinolysis. 
Methods: We categorized the 15,076 patients enrolled in a recent fibrinolytic mega-trial 
(InTIME-II) into one of 4 hierarchical, mutually exclusive groups of HF as follows: 
l=Shock (n=719, 4.6%); P=Severe (1~1062, 7.2%); 3=Mild (n=l619, 10.8%); 4=None 
